Contact: 1-215-493-0168

Wellesley Pharmaceuticals

Wellesley Pharmaceuticals, headquartered in Newtown, PA is developing an innovative, patented drug for treating nocturia (frequent urination at night), which affects about 2.2 billion people worldwide. Currently there are no drugs on the market focused on nocturia and Wellesley plans to be first to market in the space. We believe that our proprietary drug, Paxerolâ„¢, positions us to be the industry leader, addressing a massive unmet clinical need. Paxerol offers significant advancement in terms of mechanism of action relative to existing indirect treatments of nocturia and should allow us to provide relief to hundreds of millions of people.

We are Focused on Developing a Novel Combination Therapy to Treat Nocturia